Skip to main content
SpringerLink
Log in

Aktuelle Forschungsaspekte zur Ätiopathogenese der Schizophrenien

  • Chapter
Universitätskolloquien zur Schizophrenie

  • 67 Accesses

Zusammenfassung

Die Diskussionen über die Ätiopathogenese der Schizophrenien sind auch gegenwärtig noch von hoher Heterogenität und insgesamt von großer Unklarheit gekennzeichnet. Bedient man sich genereller Modelle, um sich der Ätiopathogenese der Schizophrenien zu nähern, so lassen sich Modelle mit einer einzelnen Krankheitseinheit von denen mit multiplen Krankheitseinheiten unterscheiden. Während das Modell der einzelnen Krankheitseinheit zwar durch verschiedene klinische Ausprägungen verursacht, aber durch einen einzelnen ursächlichen Mechanismus (z.B. eine Virusinfektion schädigt Feten zu unterschiedlichen Zeiten der Hirnentwicklung) beschrieben werden kann, werden die multiplen Krankheitseinheiten durch epidemiologische, genetische und bildgebende Untersuchungen gestützt. Letzteres könnte auch die üblicherweise höhere Varianz biologischer Parameter bei Patienten mit schizophrenen Psychosen erklären.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F (1993) Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150: 1731–1733

    PubMed  CAS  Google Scholar 

  2. Aparicio-Legarza MI, Davis B, Hutson PH, Reynolds GP (1998) Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients. Neurosci Lett 241: 143–146

    Article  PubMed  CAS  Google Scholar 

  3. Bandelow B, Bleich S, Kropp S (2000) Handbuch Psychopharmaka. Hogrefe, Göttingen, Bern, Toronto, Seattle

    Google Scholar 

  4. Baron M, Gruen R, Rainer JD (1985) A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. Am J Psychiatry 142: 447–455

    PubMed  CAS  Google Scholar 

  5. Bissette G, Nemeroff CB (1988) Neurotensin and the mesocorticolimbic dopamine system. In: Kalivas PW, Nemeroff CB (eds) The mesocorticolimbic system. Ann NY Acad Sci 537: 397–404

    Google Scholar 

  6. Bleich S, Spilker K, Kurth C, Degner D, Quintela-Schneider M, Javaheripour K, Rüther E, Kornhuber J, Wiltfang J (2000) Oxidative stress and an altered methionine metabolism in alcoholism. Neurosci Lett 293: 171–174

    Article  PubMed  CAS  Google Scholar 

  7. Bleich S, Degner D, Kornhuber J (2000) Repeated ethanol withdrawal delays development of focal seizures in hippocampal kindling. Alcohol Clin Exp Res 24: 244–245

    Article  PubMed  CAS  Google Scholar 

  8. Bleich S, Degner D, Wiltfang J, Maler JM, Niedmann P, Cohrs S, Mangholz A, Porzig J, Sprung R, Rüther E, Kornhuber J (2000) Elevated homocysteine levels in alcohol withdrawal. Alcohol Alcohol 35: 351–354

    Article  PubMed  CAS  Google Scholar 

  9. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuro-psychopharmacology 1: 179–186

    Article  CAS  Google Scholar 

  10. Carlsson A, Lindquist M (1963) Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanophrine in mouse brain. Acta Pharmacol 20: 140–144

    Article  CAS  Google Scholar 

  11. Carlsson A, Waters N, Hansson LO (1995) Neurotransmitter aberrations in schizophrenia: new findings. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia. An integrated view. Munks-gaard, Copenhagen, pp 332–340

    Google Scholar 

  12. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect 95: 105–111

    Google Scholar 

  13. Costa J, Khaled E, Sramek J, Bunney W Jr, Potkin SG (1990) An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 10: 71–72

    Article  PubMed  CAS  Google Scholar 

  14. Crow TJ (1984) A re-evaluation of the viral hypothesis: Is psychosis the result of retroviral integration at a side close to the cerebral dominance gene? Br J Psychiatry 145: 243–253

    Article  PubMed  CAS  Google Scholar 

  15. Deckert J, Gleiter CH (1990) Adenosinergic psychopharmaceuticals: just an extra cup of coffee? J Psychopharmacol 4: 183–187

    Article  PubMed  CAS  Google Scholar 

  16. Eastwood SL, Burnet PW, Harrison PJ (1997) GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction ( RT-PCR) study. Brain Res Mol Brain Res 44: 92–98

    Google Scholar 

  17. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47: 213–219

    Article  PubMed  CAS  Google Scholar 

  18. Feldberg (1976) Possible association of schizophrenia with a disturbance in prostaglandin metabolism. A physiological hypothesis. Psychol Med 6: 359–369

    Article  PubMed  CAS  Google Scholar 

  19. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000) Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157: 1141–1149

    Article  PubMed  CAS  Google Scholar 

  20. Garbutt JC, van Kämmen DP (1983) The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 9: 336–353

    Article  PubMed  CAS  Google Scholar 

  21. Gottesman JJ, Shields H (1982) Schizophrenia, the epigenetic puzzle. Cambridge University Press, Cambridge

    Google Scholar 

  22. Gross G, Huber G (1972) Sensorische Störungen bei Schizophrenien. Arch Psychiatr Nervenkr 216: 119–130

    Article  PubMed  CAS  Google Scholar 

  23. Heston LL (1966) Psychiatric disorders in faster home reared children of schizophrenic mothers. Br J Psychiatry 112: 819–827

    Article  PubMed  CAS  Google Scholar 

  24. Horrobin DF (1977) Schizophrenia as a prostaglandin deficiency disease. Lancet I: 936–937

    Google Scholar 

  25. Hudson CJ, Young LT, Li PP, Warsh JJ (1993) CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13: 278–293

    Article  PubMed  CAS  Google Scholar 

  26. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301–1308

    PubMed  CAS  Google Scholar 

  27. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151: 1234–1236

    PubMed  CAS  Google Scholar 

  28. Javitt DC, Balla A, Sershen H, Lajtha A (1999) A. E. Bennett Research Award. Reversal of phen-cyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45: 668–679

    Google Scholar 

  29. Karson CN, Casanova MF, Kleinman JE, Griffin WST (1993) Choline acetyltransferase in schizophrenia. Am J Psychiatry 150: 454–459

    PubMed  CAS  Google Scholar 

  30. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382

    Article  PubMed  CAS  Google Scholar 

  31. Kornhuber J, Bleich S (1999) Memantin. In: Riederer P, Laux G, Pöldinger W (Hrsg), Neuro-Psychopharmaka, Bd. 5, 2. Aufl. Springer, Wien, S 687–704

    Google Scholar 

  32. Kornhuber J, Weller M (1994) Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. Nervenarzt 65: 741–754

    PubMed  CAS  Google Scholar 

  33. Kornhuber J, Weller M (1997) Psychotogenicity and NMD A receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41: 135–144

    Article  PubMed  CAS  Google Scholar 

  34. Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenie. Nervenarzt 55: 602–606

    PubMed  CAS  Google Scholar 

  35. Kornhuber ME, Kornhuber J, Zettlmeissl H, Kornhuber HH (1986) Phencyclidin und das glutamaterge System. In: Keupp W (Hrsg) Biologische Psychiatrie, Forschungsergebnisse. Springer, Berlin, Heidelberg, New York, Tokyo, S 176–180

    Google Scholar 

  36. Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E (1989) 3H-Spiper-one binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 75: 1–10

    Google Scholar 

  37. Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989) [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236

    Google Scholar 

  38. Kornhuber J, Thome J, Riederer P (1998) Modellvorstellungen zur Ätiopathogenese der Schizophrenien. In. Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd. 4, 2. Aufl. Springer, Wien

    Google Scholar 

  39. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR (1987) Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 20: 337–345

    Article  PubMed  CAS  Google Scholar 

  40. Lieberman JA, Koreen AR (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19: 371–429

    Article  PubMed  CAS  Google Scholar 

  41. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurological disorders. N Eng J Med 330: 613–622

    Article  CAS  Google Scholar 

  42. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99: S18 - S27

    Article  PubMed  Google Scholar 

  43. Nair NPV, Lal S, Bloom DM (1994) Cholecystokinin and schizophrenia. In: van Ree JM, Matthysse S (eds) Progress in brain research, vol. 65. Elsevier, Amsterdam, pp 237–258

    Chapter  Google Scholar 

  44. Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360–1362

    Article  PubMed  CAS  Google Scholar 

  45. Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2 (8083): 223–226

    Article  PubMed  CAS  Google Scholar 

  46. Pearlson GD (1981) Psychiatric and medical syndromes with phencyclidine (PCP) abuse. Johns Hopkins Med J 148: 25–33

    PubMed  CAS  Google Scholar 

  47. Reynolds GP (1989) Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br J Psychiatry 155: 305–316

    PubMed  CAS  Google Scholar 

  48. Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F (1996) The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophr Res 20: 171–174

    Article  PubMed  CAS  Google Scholar 

  49. Seeman P, Guan HC, Van Tol HH (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365 (6445): 441–445

    Article  PubMed  CAS  Google Scholar 

  50. Serval V, Galli T, Cheramy A, Glowinski J, Lavielle S (1992) In vitro and in vivo inhibition of N-acetyl-L-aspartyl-L-glutamate catabolism by N-acylated L-glutamate analogs. J Pharmacol Exp Ther 260: 1093–1100

    PubMed  CAS  Google Scholar 

  51. Simeon J, Fink M, Itil TM, Ponce D (1970) d-Cycloserine therapy of psychosis by symptom provocation. Compr Psychiatry 11: 80–88

    Article  PubMed  CAS  Google Scholar 

  52. Svensson A, Carlsson ML, Carlsson A (1992) Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. J Neural Transm 88: 235–240

    Article  CAS  Google Scholar 

  53. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46: 745–753

    Google Scholar 

  54. Terenius L, Wahlström A, Lindström L, Widerlov E (1976) Increased CSF levels of endorphins in chronic psychoses. Neurosci Lett 3: 157–162

    Article  PubMed  CAS  Google Scholar 

  55. Trist DG (2000) Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications. Pharm Acta Helv 74: 221–229

    Article  PubMed  CAS  Google Scholar 

  56. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52: 829–836

    Article  PubMed  CAS  Google Scholar 

  57. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355–402

    PubMed  CAS  Google Scholar 

  58. Waziri R (1988) Glycine therapy of schizophrenia. Biol Psychiatry 23: 210–211

    Article  PubMed  CAS  Google Scholar 

  59. Wiegant VM, Ronken E, Kovacs G, de Wied D (1992) Endorphins and schizophrenia. Prog Brain Res 93: 433–453

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Kornhuber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Bleich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, Nußbaumstr. 7, 80336, München, Deutschland

    Hanns Hippius (em. o. Professor für Psychiatrie) (em. o. Professor für Psychiatrie)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kornhuber, J., Bleich, S. (2003). Aktuelle Forschungsaspekte zur Ätiopathogenese der Schizophrenien. In: Hippius, H. (eds) Universitätskolloquien zur Schizophrenie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57417-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57417-7_22

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63263-1

  • Online ISBN: 978-3-642-57417-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation